Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is there hope, you decide:
http://www.marketwire.com/press-release/Dnaprint-Genomics-Inc-778556.html
Ann
DNAPrint & Bioserve (hit big time?):
http://www.thegeneticgenealogist.com/2007/10/18/dnaprint-and-bioserve-600000-genetic-genealogy-tests/
Ann
Has anyone tried ordering from this page?:
http://www.dnaprint.com/welcome/home/index.php
Ann
sd:
I got the info from the link you posted.
Take care,
Ann
sd34:
So what does the following imply?
CALCULATION OF REGISTRATION FEE
Title of each class of securities to be registered Amount of
shares to be registered (1) Proposed offering price per share (2) Proposed maximum aggregate offering price Amount of registration fee (3)Common stock, to be sold by existing shareholders 82,500,000 $0.01 $825,000 $25.58 (1) Pursuant to
Rule 416(a) of the Securities Act of 1933, as amended, this registration statement shall be deemed to cover additional securities that may be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.
(2) The price of $0.01 per share, which was the average of the high and low prices of the Registrant's common stock, as reported on the Over-The-Counter Bulletin Board on May 31, 2007 is set forth solely for purposes of calculating the registration fee pursuant to Rule 457(c) of the Securities Act of 1933, as amended.
(3) $38.75 previously paid. No additional payment required.
The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.
The information contained in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is declared effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
Ann
Thank you, ucca.
Happy Holidays to all!
Ann
Frog:
Just wanted to be sure about the existence of 10% DNAP held.
Ann
Frog:
"DNAG sold it's stake in Biofrontera and no longer has a connection".
Can you provide a link to that?
Take care,
Ann
TY, Bag.
Ann
23andMe under scrutiny:
http://www.redorbit.com/news/health/1437305/genetic_testing_companies_under_scrutiny/
Ann
Take a look at this. Dated 8/08:
In a study published last year, Mark Shriver and his team at Pennsylvania State University analyzed 10,000 genetic markers in nearly 300 people of Armenian, Jewish, Greek, Spanish, Basque, French, Italian, German, English, Irish, Polish, and Finnish descent. They found that genetic profiles differed from north to south and east to west. "Genetic displays seem to fit with geographic features of a map," says Shriver, who is also a consultant for DNAprint, a genetic-testing company in Sarasota, FL. For example, the Iberian Peninsula, isolated from the rest of Europe by the Pyrenees, seems to harbor a distinct genetic profile.And areas in the middle of Europe have a profile somewhere between that of the north and the south.
Two companies have already condensed those findings into commercial tests: DNAprint and 23andMe, a personal-genomics startup based in Mountain View, CA. DNAprint's European service uses a subset of 1,349 genetic variations from the original 10,000 to classify an individual's ancestry according to five groups: southeastern European, Iberian, Basque, continental European, and northeastern European. 23andMe, which offers ancestry analysis as part of a broader genetic screening service, estimates users' genetic similarity to 14 different populations around the world, including northern and southern Europeans.
Consumer ancestry testing, however, remains far from exact. All genetic ancestry tests are probabilistic: while individual markers might be more likely to appear in certain populations, that is not always the case, meaning that not everyone who carries that variation has ancestors in that group.
And the profile that a particular service spits out depends on the database used to calculate it. DNAprint offers a $240 global ancestry test, AncestryByDNA 2.5, that analyzes 176 markers derived mainly from studies of four groups: Native Americans, East Asians, West Africans, and Europeans. Because those groups have contributed most heavily to the current U.S. population, the test works best for people in the States.
Ann
Dan:
You have a wonderful holiday season!
I hope all others here will have the same!
Take care,
Ann
Does anyone know if this venture is still on?
"DNAPrint gets California partner
STAFF REPORT
HeraldTribune.com
http://www.heraldtribune.com/article/20071116/BUSINESS/711160459
SARASOTA -- DNAPrint Genomics Inc. will be offering its genetics
testing kits along with a big California company's genotyping systems.
The Sarasota-based DNAPrint, which makes ancestry and forensics
genetics testing kits, said it had signed a sales and marketing
agreement with Beckman Coulter Inc., a $2.3 billion company based in Fullerton, Calif.
The focus of the agreement is the company's DNAWitness and Ancestry
DNA tests.
Ancestry DNA technology can determine genetic ancestry and provide law enforcement a "fuzzy photograph" of an individual from a DNA sample.
"As a primary focus, DNAPrint can provide detectives with the new DNAWitness descriptor kit that their own crime labs can run," said Richard Gabriel, chief executive and president of DNAPrint, in a Thursday statement.
Forensic investigators can use the technology to acquire a description of a suspect or to help them identify unknown victims.
Beckman Coulter is providing its SNPStream system for the venture with DNAPrint. It is a product that validates DNA testing and identification used to predict drug reactions in certain population groups, Gabriel said.
Ann
Again, we guess.
Take care,
Ann
On FOX News just now is "one" of the forensic tests to be conducted is the determination of race of the body found, believed, (at this point) to be Caylee.
Ann
Sam:
Why not post the list of current AncestrybyDNA distribution links. That may be somewhat of a help to him. (Better than nothing, as we say in bingo). lol
Take care,
Ann
Here's what's currently listed on DNAP's website as Core Technology:
http://www.dnaprint.com/welcome/science/
Ann
Another factor is that DNAP stated that DNAWitness should be used "early" into a case.
Ann
Dan:
Interesting, I had assumed the same slant as you when reading about the application of the DNA procedure in the Anchorwoman case.
Take care,
Ann
Dan:
Very well put.
I am keeping the faith. - lol
Take care,
Ann
Sam:
I remember at the inception and the waning years of our DNAP stock and R & D into the current market place, approx. 10 yrs. ago, when I became an investor, there was a quoted realistic projection for any benefits & developments to take center stage that projected over 10 yrs. into the future. So, therefore, at that time, I decided, to trial out where I was fit in going in with my investment. I reasoned to weather the storm and ride it out to the end. I currently have been skeptically waiting for DNAP to fold, largely due to current events, but, am in nature, optimistic! I have been anticipating in closing my account if necessary, which has not yet transpired, but, as a consequence, if this sequence does occur, I hope I will not be in denial of anything...just awaiting one way...or the other...as I also logically can concede it may affect others. Very much luck to everyone.
My experience on this board has been exceptionally meaningful to me all of these years!
Take care,
Ann
TY, Sam
Ann
We still seem to own 10 percent of Biofrontera. Anyone's comments on this:
http://www.bizjournals.com/tampabay/stories/2006/11/20/daily33.html
Ann
DNAP listed as a member of PMC, which is in previous AP article, under Diagnostic Companies:
http://www.personalizedmedicinecoalition.org/about/pmc_members.php
Ann
FSail:
Perhaps, you are referring to the following article put out by AP on 11/28:
Obama to broaden role of genetics in medical care
By RICARDO ALONSO-ZALDIVAR, Associated Press Writer
For years, scientists have held out hope that the rapidly evolving field of genetics could transform medical diagnosis and treatment, moving beyond a trial-and-error approach as old as the Hippocratic Oath.
But the vision of individualized treatment based on a patient's genetic makeup and other biological markers has yet to materialize, even if better use of genetic information has led to advances in cancer care and other areas.
Now the pursuit of "personalized medicine" is expected to get a major push from the incoming administration of President-elect Barack Obama. As a senator, Obama introduced legislation to coordinate the sometimes conflicting policies of government agencies and provide more support for private research. He remains keen on the idea.
"The president-elect has indicated his support for both advancing personalized medicine and increasing (research) funding," said Rep. Patrick J. Kennedy, D-R.I., who has introduced legislation in the House that builds on Obama's.
Obama is also interested in the role that personalized medicine could play as an element of changes in the broader health care system.
"The issue of getting the right treatment to the right person goes with his whole emphasis on health reform," said Mark McClellan, a noted Republican health care expert who served President George W. Bush as Medicare director and head of the Food and Drug Administration. "If we're thinking about reforming the health care system, we should be thinking about what medicine will be like down the road when health care reform is fully implemented," McClellan said.
Although medical science is more technologically advanced than at any time in history, in some ways it is still strikingly old-fashioned. For example, most prescription drugs are effective only in about 60 percent of treated patients, leading to a trial-and-error approach to treatment that not only may be more costly, but can put some patients at risk.
Among patients, the varying responses to medications may be linked to differences in genetic makeup that affect how the body processes a drug. For example, the FDA recently warned that certain drugs for epileptic seizures may prompt a severe skin reaction in Asian patients because of a genetic trait. The practice of medicine could be streamlined if doctors had reliable ways of predicting which drugs would work on which individuals.
Government funding for research helped make possible many of the scientific gains in genetics, and Congress has passed landmark legislation outlawing discrimination against patients on the basis of genetic information.
But the mundane decisions, such as whether or not to pay for some genetic tests, have not progressed that smoothly.
For example, the FDA supported research that found certain genes can make some patients taking the blood thinner Coumadin susceptible to potentially fatal bleeding. The agency has been pushing for some time to make doctors aware of genetic tests that could help their patients.
But Medicare has not yet set a national policy on paying for the tests. Problems with Coumadin, also known as warfarin, are a major cause of emergency room visits for seniors.
"It would be very helpful if you could get (Medicare) and FDA talking to each other," said Edward Abrahams, executive director of the Personalized Medicine Coalition. "Right now they really don't communicate very well, and they have different agendas. The federal government is not coordinated around removing the barriers to personalized medicine." His group represents university research centers, industry and patients.
Obama's legislation would create an interagency group to coordinate the policies of federal agencies whose decisions have an impact on the issue. Kennedy also would direct Medicare to set a fixed policy for coverage of genetic tests and treatments.
Both bills would establish a national 'Biobank' to pool data that could serve as a resource for scientific researchers, and the legislation also calls for increases in federal funding. Obama has proposed a 100 percent tax credit for private research to develop diagnostic tests that can predict the safety and effectiveness of certain high profile drugs.
"So far, we haven't really seen any transformation of medicine," said McClellan. "There are some real questions to deal with to see if there is some policy that could speed it up.
Take care,
Ann
The Genetic Alliance’s Terry said that Obama “has surrounded himself with Nobel Laureates and seasoned domain experts to advise the campaign,” and she called the emphasis on science as a primary domestic agenda “unprecedented.” Genetic Alliance views the campaign’s specific set of advisors as representatives of “a tipping point” for genetics and genomics in public policy, she added.
The president-elect also introduced last year a genomics and personalized medicine bill that, in its 2008 form, would promote genomics and pharmacogenomics studies in government, offer tax credit incentives for genomics research, would start a biobanking initiative, and would aim to develop some oversight for genetic testing.
This bill expired last year and was re-introduced this year by Representative Patrick Kennedy (D – RI) and will be a priority, Hughes said at a meeting on Capitol Hill in July with the Genetic Alliance.
Hughes also said at that meeting that some parts of the bill could be done through other channels if Obama were to win the White House. Terry thinks that the new president could use the executive order privilege “to make things happen quickly and to enforce a sound public approach that could have a profound impact.”
The Kennedy bill would create a Genomics and Personalized Medicine Interagency Working Group that would include the National Institutes of Health, the Food and Drug Administration, the Centers for Disease Control and Prevention, and other groups outside of the Department of Health and Human Services.
The National Biobanking Initiative would create a database for collecting and integrating genomics and environmental health data and information. Another section would use funding to improve diagnosis of genetic diseases, and for treatment and counseling. Rep. Kennedy also has added a tax credit for research expenses incurred in the development of a companion diagnostic test.
“As the bill identifies, incentives are necessary for us to realize the potential of personalized medicine,” PMC’s Miller explained. Miller also said that two other ideas PMC has proposed are in one version of the act, including a tax credit for R&D costs and “a streamlined process through FDA for drug-diagnostic tests for pharmaceuticals.”
The bill also proposes using a matrix of oversight for regulating genetic and pharmacogenomic tests, which Terry calls “a mindful approach” that is aware “of the need not to over-regulate this emerging technology.”
“Obama has been one of the foremost leaders in considering genomics and personalized medicine, and this is a great opportunity to work with an administration that’s aware of these issues,” BIO’s Pritchard added.
As an example, Pritchard said, “The genomics bill has specific provisions, and that’s why we can have this conversation about what can be enacted, legislative or executive.”
The Obama administration also is expected to continue the Personalized Health Care initiative that was started by current Department of Health and Human Services Secretary Michael Leavitt. That program aims to link clinical and genomic information, support genetic information discrimination law, ensure accuracy and validity of genetic tests, and develop common policies for access to genomic databases.
Terry told GWDN that the Obama campaign said it expected to continue the PHC initiative at least beyond the beginning of 2009, and that Genetic Alliance hopes that the new administration will “bring discipline and focus to the program” and will be able to effect real change that makes a difference in real health outcomes.
“Personalized medicine could become a catch phrase that becomes a parking lot for hype,” Terry warned. “It is essential it is grounded in the needs of real patients and real healthcare providers – it is transformative, but only when it is also practical and accessible,” she said.
Take care,
Ann
I meant FSail...more...
Ann
I posted this a while back Big:
"The funding question, particularly for the National Institutes of Health, will be the most pressing. President-elect Obama will arrive to the Oval Office in the midst of a financial crisis, and will be confronted with a 2009 federal budget that has yet to be agreed upon.
NIH "has been historically challenged, regardless of the funding amounts, with doing more than just basic biomedical research,” Genetic Alliance President and CEO Sharon Terry told GenomeWeb Daily News on Thursday.
Terry also thinks that the Chicago politician’s “integrated vision for a modern, evidence-based and effective health care delivery system … can only mean positive things for personalized medicine products and services.”
More...
Ann
You can keep scrolling down on the link you sent, Sam,and read the comments or send your own.
Take care,
Ann
Pull down Playlist and highlight Race. You're right, Monkey.
Ann
Can't get access, either.
Ann
Hopefully!
Ann
Dan:
I wonder if Pres.-elect Obama would be interested in accessing this information in his assessment & ambition of revamping the health-care industry?
(half-way serious - lol)
Take care,
Ann
Cheers, to you, Dan...(and us?)
Take care,
Ann
A video on YouTube on Personalized Medicine. (Looks like it has recently surfaced from '06). If you have time to watch it through, you will find it extremely informative as to what DNAP is/was involved in and evolving to grow into as a pharmaceutical co.
The speaker's presentation is excellent and she definitely keeps up the viewer's interest.
Altar:
We can keep our toes crossed, can't we? - lol
Good to hear from you and...
Take care,
Ann
Thanx, Dan...
Having a nice weekend.
Take care,
Ann